AGIO
AGIO clinical trials: AGIOS PHARMACEUTICALS, INC.
Every trial on ClinicalTrials.gov where AGIOS PHARMACEUTICALS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 60
- Trials linked
- 52
- As lead sponsor
- 8
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
AGIO on the catalyst calendar · AGIO registry changes
- Primary completion Nov 13, 2023ActualPhase 3NCT04770753A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or...Agios Pharmaceuticals, Inc. · Non-Transfusion-dependent Alpha-ThalassemiaActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 3NCT07506863A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent...Agios Pharmaceuticals, Inc. · Transfusion-dependent Alpha-ThalassemiaRecruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2029Sponsor estimatePhase 3NCT07656415A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)Agios Pharmaceuticals, Inc. · Sickle Cell DiseaseRecruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 3NCT07517133A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or...Agios Pharmaceuticals, Inc. · Non-Transfusion-dependent Alpha-ThalassemiaRecruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 17, 2028Sponsor estimatePhase 1NCT07241234A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With PhenylketonuriaAgios Pharmaceuticals, Inc. · PhenylketonuriaRecruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 12, 2026ActualPhase 2NCT06924970A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)Agios Pharmaceuticals, Inc. · Sickle Cell DiseaseActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2029Sponsor estimatePhase 4NCT05777993A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat StudyAgios Pharmaceuticals, Inc. · Pyruvate Kinase DeficiencyEnrolling by invitationAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 13, 2024ActualPhase 3NCT05175105A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not...Agios Pharmaceuticals, Inc. · Pediatric Pyruvate Kinase DeficiencyActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 3, 2024ActualPhase 3NCT05144256A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are...Agios Pharmaceuticals, Inc. · Pediatric Pyruvate Kinase DeficiencyActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 11, 2024ActualPhase 3NCT04770779A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)Agios Pharmaceuticals, Inc. · Transfusion-dependent Alpha-ThalassemiaActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 31, 2027Sponsor estimateNo phase registeredNCT03481738Pyruvate Kinase Deficiency Global Longitudinal RegistryAgios Pharmaceuticals, Inc. · Pyruvate Kinase DeficiencyActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 30, 2025ActualPhase 2/Phase 3NCT05031780A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)Agios Pharmaceuticals, Inc. · Sickle Cell DiseaseActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2030Sponsor estimatePhase 2/Phase 3NCT07859423A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia VeraAgios Pharmaceuticals, Inc. · Polycythemia VeraNot yet recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 17, 2026ActualPhase 2NCT05490446A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)Agios Pharmaceuticals, Inc. · Myelodysplastic SyndromesActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 11, 2026ActualPhase 1NCT07075640A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy...Agios Pharmaceuticals, Inc. · Healthy ParticipantsActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 8, 2017ActualPhase 2NCT02476916A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyAgios Pharmaceuticals, Inc. · Pyruvate Kinase DeficiencyCompletedAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 2NCT06286046A Study of Mitapivat in Participants With Sickle Cell Disease and NephropathyAgios Pharmaceuticals, Inc. · Sickle Cell DiseaseWithdrawnAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 20, 2020ActualPhase 2NCT03692052A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With...Agios Pharmaceuticals, Inc. · ThalassemiaActive, not recruitingAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 9, 2025ActualPhase 1NCT06286033Single and Multiple Ascending Dose Study and Food Effect Study for AG181Agios Pharmaceuticals, Inc. · Healthy VolunteersCompletedAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 3, 2024ActualPhase 3NCT03853798Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007Agios Pharmaceuticals, Inc. · Pyruvate Kinase DeficiencyCompletedAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 21, 2025ActualPhase 1NCT06745271A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made...Agios Pharmaceuticals, Inc. · Healthy ParticipantsCompletedAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2024ActualPhase 1NCT06648824Study of How Mitapivat Affects Midazolam Blood Levels in Healthy ParticipantsAgios Pharmaceuticals, Inc. · Healthy ParticipantsCompletedAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 19, 2023ActualPhase 1NCT04536792A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants...Agios Pharmaceuticals, Inc. · Healthy VolunteersCompletedAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 22, 2023ActualNo phase registeredNCT04995315Pyruvate Kinase Deficiency Global Longitudinal Registry Substudy of Protocol AG348-C-008Agios Pharmaceuticals, Inc. · Pyruvate Kinase DeficiencyCompletedAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 21, 2023ActualPhase 1NCT05610657A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants...Agios Pharmaceuticals, Inc. · Moderate Hepatic ImpairmentCompletedAGIOLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 35 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner